External Quality Assessment of 24,25-dihydroxyvitamin D3 (24,25(OH)2D3) assays

Abstract

The discovery that mutations of the CYP24A1 gene are a cause of idiopathic infantile hypercalcemia (IIH) has revived interest in measuring serum 24,25(OH)₂D₃. Several studies have also suggested that a high 25-hydroxyvitamin D₃(25-OHD₃):24,25(OH)₂D₃ ratio might provide additional diagnostic information in the investigation of vitamin D deficiency. Measurement of 24,25(OH)₂D₃ is necessarily restricted to laboratories with mass spectrometry methods although cross reactivity of the metabolite in immunoassays for 25-OHD is a potential cause of misleading results. The international External Quality Assessment (EQA) scheme for vitamin D metabolites (DEQAS) was set up in 1989. In 2013 DEQAS became an accuracy based EQA for 25-OHD with 'target values' assigned by the National Institute of Standards and Technology (NIST) Reference Measurement Procedure (RMP). A pilot scheme for serum 24,25(OH)₂D₃ was started in 2015 and participants were asked to measure the metabolite on each of the 5 samples sent out for 25-OHD. Inter-laboratory agreement was poor but this may reflect methodological differences, in particular different approaches to assay standardization. An important potential contribution to reducing variability among assays was the development by NIST of a 24,25(OH)₂D₃ RMP and its use in assigning values to SRMs 972a, 2973 and 2971, supported by the NIH Office of Dietary Supplements (ODS) as part of the Vitamin D Standardization Program (VDSP) effort.

Keywords: 24,25-Dihydroxyvitamin D; 25-Hydroxyvitamin D; 25-OHD(3):24,25(OH)(2)D(3) ratio; DEQAS; Hypercalcemia; National Institute of Standards and Technology (NIST); Vitamin D Standardization Program (VDSP).